Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

965 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
Chou T, Ishiguro T, Imajo K, Kawano F, Gondo H, Kasai M, Masuda M, Koike M, Shimazaki C, Hara M, Shinagawa K, Ogawa M, Takaku F, Harada M. Chou T, et al. Among authors: ishiguro t. Rinsho Ketsueki. 1999 Oct;40(10):1058-67. Rinsho Ketsueki. 1999. PMID: 10565222 Clinical Trial. Japanese.
Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial.
Isoda A, Murayama K, Ito S, Kohara Y, Iino M, Miyazawa Y, Matsumoto M, Handa H, Imai Y, Ishiguro T, Izumita W, Kitano K, Hirabayashi Y, Nakazawa H, Ishida F, Mitsumori T, Kirito K, Chou T, Murakami H; Kanshinetsu Multiple Myeloma Study Group. Isoda A, et al. Among authors: ishiguro t. Int J Hematol. 2018 Jul;108(1):39-46. doi: 10.1007/s12185-018-2448-9. Epub 2018 Mar 28. Int J Hematol. 2018. PMID: 29594921 Clinical Trial.
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Watanabe T, et al. Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8. Lancet Haematol. 2018. PMID: 30389034 Clinical Trial.
The 31-nucleotide Y4-RNA fragment in plasma is a potential novel biomarker.
Ishikawa T, Haino A, Seki M, Kurihara T, Hirose T, Imai Y, Ishiguro T, Chou T, Toshima M, Terada H, Nashimoto M. Ishikawa T, et al. Among authors: ishiguro t. Noncoding RNA Res. 2019 Dec 17;5(1):37-40. doi: 10.1016/j.ncrna.2019.12.001. eCollection 2020 Mar. Noncoding RNA Res. 2019. PMID: 32206739 Free PMC article.
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.
Ishida T, Kuroda Y, Matsue K, Komeno T, Ishiguro T, Ishikawa J, Ito T, Kosugi H, Sunami K, Nishikawa K, Shibayama K, Aida K, Yamazaki H, Inagaki M, Kobayashi H, Iida S. Ishida T, et al. Among authors: ishiguro t. Int J Hematol. 2024 Nov 28. doi: 10.1007/s12185-024-03884-z. Online ahead of print. Int J Hematol. 2024. PMID: 39607603
965 results